We found that higher scores were associated with worse OS and PFS, with a significant trend ( p for trend < 0.001).
← all excerpts
Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab.
1
—
—
We found that higher scores were associated with worse OS and PFS, with a significant trend ( p for trend < 0.001).